UroGen Pharma to Present at Upcoming Investor Conferences
UroGen Pharma (Nasdaq: URGN), a biotech company focused on urothelial and specialty cancers, has announced its participation in two upcoming investor conferences. The company will engage in fireside chats at:
1. The H.C. Wainwright 26th Annual Global Investment Conference on September 9th, 2024, at 9:00am ET in New York, NY.
2. The 2024 Cantor Global Healthcare Conference on September 18, 2024, at 3:40pm ET, also in New York, NY.
Webcasts of both events will be accessible through UroGen's website investor section, with replays available for approximately 90 days. This participation provides investors an opportunity to gain insights into UroGen's innovative cancer treatment solutions and business strategies.
UroGen Pharma (Nasdaq: URGN), una società biotecnologica focalizzata su tumori uroteliali e speciali, ha annunciato la sua partecipazione a due prossime conferenze per investitori. L'azienda parteciperà a discussioni informali in:
1. La 26ª Conferenza Globale di Investimento Annuale H.C. Wainwright il 9 settembre 2024, alle 9:00 ET a New York, NY.
2. La Conferenza Globale sulla Sanità Cantor 2024 il 18 settembre 2024, alle 15:40 ET, sempre a New York, NY.
Le dirette di entrambi gli eventi saranno accessibili tramite la sezione investitori del sito web di UroGen, con repliche disponibili per circa 90 giorni. Questa partecipazione offre agli investitori un'opportunità di ottenere informazioni sulle innovative soluzioni per il trattamento del cancro e sulle strategie aziendali di UroGen.
UroGen Pharma (Nasdaq: URGN), una empresa biotecnológica centrada en cánceres uroteliales y especiales, ha anunciado su participación en dos próximas conferencias para inversores. La empresa participará en charlas informales en:
1. La 26ª Conferencia Global Anual de Inversión de H.C. Wainwright el 9 de septiembre de 2024, a las 9:00 ET en Nueva York, NY.
2. La Conferencia Global de Salud Cantor 2024 el 18 de septiembre de 2024, a las 15:40 ET, también en Nueva York, NY.
Las transmisiones en vivo de ambos eventos estarán disponibles a través de la sección de inversores del sitio web de UroGen, con repeticiones disponibles durante aproximadamente 90 días. Esta participación ofrece a los inversores la oportunidad de obtener información sobre las innovadoras soluciones de tratamiento del cáncer y las estrategias comerciales de UroGen.
UroGen Pharma (Nasdaq: URGN)는 요로 세포 및 특수 암에 중점을 둔 생명 공학 회사로, 두 개의 다가오는 투자자 컨퍼런스에 참여한다고 발표했습니다. 이 회사는 다음 행사에서 파이어사이드 채팅에 참여할 예정입니다:
1. H.C. Wainwright 제26회 연례 글로벌 투자 컨퍼런스가 2024년 9월 9일 오전 9시(ET)에 뉴욕, NY에서 개최됩니다.
2. 2024 Cantor 글로벌 헬스케어 컨퍼런스가 2024년 9월 18일 오후 3시 40분(ET)에도 뉴욕, NY에서 열릴 예정입니다.
두 이벤트의 웹캐스트는 UroGen의 웹사이트 투자자 섹션을 통해 접근할 수 있으며, 재방송은 약 90일 동안 이용 가능합니다. 이번 참여는 투자자들에게 UroGen의 혁신적인 암 치료 솔루션과 사업 전략에 대한 통찰력을 얻을 수 있는 기회를 제공합니다.
UroGen Pharma (Nasdaq: URGN), une entreprise biopharmaceutique axée sur les cancers urotéliaux et spécialisés, a annoncé sa participation à deux conférences pour investisseurs à venir. L'entreprise participera à des discussions informelles lors des événements suivants :
1. La 26e Conférence Annuelle Mondiale de l'Investissement H.C. Wainwright le 9 septembre 2024, à 9h00 ET à New York, NY.
2. La Conférence Mondiale sur la Santé Cantor 2024 le 18 septembre 2024, à 15h40 ET, également à New York, NY.
Les retransmissions en direct des deux événements seront accessibles via la section investisseurs du site web d'UroGen, avec des rediffusions disponibles pendant environ 90 jours. Cette participation offre aux investisseurs une opportunité d'obtenir des informations sur les solutions innovantes de traitement du cancer et les stratégies commerciales d'UroGen.
UroGen Pharma (Nasdaq: URGN), ein Biotechnologieunternehmen, das sich auf uroteliale und spezialisierte Krebserkrankungen konzentriert, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen angekündigt. Das Unternehmen wird in folgenden Veranstaltungen an Fireside-Chats teilnehmen:
1. Die 26. jährliche globale Investorenkonferenz von H.C. Wainwright am 9. September 2024 um 9:00 Uhr ET in New York, NY.
2. Die 2024 Cantor Global Healthcare Conference am 18. September 2024 um 15:40 Uhr ET, ebenfalls in New York, NY.
Webcasts beider Veranstaltungen werden über den Investorenbereich der UroGen-Website zugänglich sein, mit Wiederholungen, die etwa 90 Tage lang verfügbar sind. Diese Teilnahme bietet den Investoren die Möglichkeit, Einblicke in UroGens innovative Lösungen zur Krebsbehandlung und Geschäftstrategien zu gewinnen.
- None.
- None.
- H.C. Wainwright 26th Annual Global Investment Conference -
- 2024 Cantor Global Healthcare Conference -
H.C. Wainwright 26th Annual Global Investment Conference – September 9-11th, 2024
Fireside Chat: September 9th, 2024 at 9:00am ET
Location:
Webcast Registration Link: Here
2024 Cantor Global Healthcare Conference – September 17-19th, 2024
Fireside Chat: September 18, 2024 at 3:40pm ET
Location:
Webcast Registration Link: Here
A webcast from the conference will also be available via the Investors section of UroGen’s website, www.urogen.com. A replay of the webcast will be available for approximately 90 days.
About UroGen Pharma Ltd.
UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel® reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. Our first product to treat low-grade upper tract urothelial cancer and investigational treatment UGN-102 (mitomycin) for intravesical solution for patients with LG-IR-NMIBC are designed to ablate tumors by non-surgical means. UroGen is headquartered in
View source version on businesswire.com: https://www.businesswire.com/news/home/20240829971223/en/
INVESTOR CONTACT:
Vincent Perrone
Senior Director, Investor Relations
vincent.perrone@urogen.com
609-460-3588 ext. 1093
MEDIA CONTACT:
Cindy Romano
Director, Corporate Communications
cindy.romano@urogen.com
609-460-3583 ext. 1083
Source: UroGen Pharma Ltd.
FAQ
When is UroGen Pharma (URGN) presenting at the H.C. Wainwright Global Investment Conference?
What is the date and time of UroGen Pharma's (URGN) fireside chat at the Cantor Global Healthcare Conference?
How long will the webcasts of UroGen Pharma's (URGN) investor conference presentations be available?
Where can investors access the webcasts of UroGen Pharma's (URGN) conference presentations?
